Innovative Russian technologies show promise against Glioma brain tumors
The Russian Ministry of Science and Higher Education revealed that a multidisciplinary team of scientists and physicians has made significant progress in the development of innovative tools for the diagnosis and treatment of gliomas, a common and highly challenging category of brain tumors.
According to a ministry representative, one of the most promising advances involves the use of positron emission tomography/computed tomography (PET/CT) in combination with a novel radiopharmaceutical currently under development. The compound is based on radiolabeled aptamer molecules, which are designed to selectively target tumor tissue with high precision.
Researchers explained that, following intravenous administration, these aptamers accumulate specifically within tumor sites, enabling highly accurate visualization and localization of malignant tissue during imaging procedures. This targeted approach may enhance diagnostic accuracy and facilitate earlier intervention.
In addition to diagnostic applications, the research team has developed therapeutic formulations that combine aptamer molecules with anti-cancer agents. These formulations are intended to improve the delivery of treatment directly to glioma cells, potentially increasing therapeutic efficacy while reducing damage to healthy tissues.
The scientists have also identified several aptamer variants capable of enhancing the sensitivity of cancer cells to radiotherapy. Furthermore, these molecules may help inhibit tumor invasion into surrounding healthy brain tissue, a development that could prolong patient survival and reduce the likelihood of tumor recurrence.
In a related development, Professor Galina Pavlova noted that researchers are investigating an alternative therapeutic strategy based on the reprogramming of cancer cells through a specific combination of molecular compounds.
According to Pavlova, these compounds may transform malignant cells into cells resembling normal brain tissue that have lost their ability to divide. She emphasized that the approach has demonstrated encouraging preliminary results and is currently undergoing patent registration procedures while preparations are being made for preclinical testing.
If successfully validated in future studies, these innovations could represent a significant step forward in precision medicine for brain cancer, offering new diagnostic and therapeutic options for patients with gliomas.
